{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T08:40:46Z","timestamp":1776501646539,"version":"3.51.2"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40265-026-02287-0","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:00:23Z","timestamp":1770883223000},"page":"551-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bevifibatide: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"1","key":"2287_CR1","first-page":"55","volume":"13","author":"RA Byrne","year":"2024","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2024;13(1):55\u2013161.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"1","key":"2287_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11596-009-0103-7","volume":"29","author":"H Chen","year":"2009","unstructured":"Chen H, Qiao J, Li Q, et al. Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects. J Huazhong Univ Sci Technol Med Sci. 2009;29(1):12\u20138.","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"2287_CR3","unstructured":"Bio-Thera Solutions. Bevifibatide Bio-Thera Solutions: product information. 2024. https:\/\/www.bio-thera.com\/uploads\/soft\/240703\/3-240F3143446.pdf. Accessed 27 Jan 2026."},{"key":"2287_CR4","unstructured":"Japan Pharmaceutical Manufacturers Association (JPMA). National Drug Administration approves launch of bevifibatide citrate injection. 2024. http:\/\/www.cjpi.org.cn\/zryyxxwjp\/yaop\/jgdt\/webinfo\/2024\/07\/1719735273070821.htm. Accessed 27 Jan 2026."},{"key":"2287_CR5","unstructured":"National Medical Products Administration. National Medical Products Administration approves bevifibatide citrate injection for marketing. Media release. 2024. http:\/\/www.nmpa.gov.cn."},{"key":"2287_CR6","unstructured":"Baotai Biological Pharmaceutical Co Ltd. Batifiban injection and preparation thereof. 2012. https:\/\/patents.google.com\/patent\/CN103656616A\/en?oq=CN103656616A. Accessed 27 Jan 2026."},{"key":"2287_CR7","unstructured":"Bio-Thera Solutions Ltd. Biological effect detection method for integrin GP IIb\/IIIa specific binding molecule Batifiban. 2013. https:\/\/patents.google.com\/patent\/CN103969228A\/en?oq=CN103969228A. Accessed 27 Jan 2026."},{"issue":"3","key":"2287_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S0008-6363(97)00184-3","volume":"36","author":"SS Srivatsa","year":"1997","unstructured":"Srivatsa SS, Fitzpatrick LA, Tsao PW, et al. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res. 1997;36(3):408\u201328.","journal-title":"Cardiovasc Res"},{"issue":"5","key":"2287_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s11596-013-1198-4","volume":"33","author":"XM He","year":"2013","unstructured":"He XM, Zhou Y, Li J, et al. Pharmacokinetic and pharmacodynamic properties of batifiban coadministered with antithrombin agents in Chinese healthy volunteers. J Huazhong Univ Sci Technol Med Sci. 2013;33(5):786\u201390.","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"issue":"1","key":"2287_CR10","first-page":"11","volume":"27","author":"J Huang","year":"2013","unstructured":"Huang J, Qian H-Y, Li Z-Z, et al. Effects of batifiban on platelet aggregation during percutaneous coronary intervention in acute coronary syndrome patients. J Chin Pract Diagn Ther. 2013;27(1):11\u20133.","journal-title":"J Chin Pract Diagn Ther"},{"issue":"18","key":"2287_CR11","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIR.0b013e31820f2f3e","volume":"123","author":"RS Wright","year":"2011","unstructured":"Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF\/AHA focused update of the guidelines for the management of patients with unstable angina\/ non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2011;123(18):2022\u201360.","journal-title":"Circulation"},{"key":"2287_CR12","unstructured":"Bio-Thera Solutions. A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to confirm the efficacy and safety of Batifiban injection in ACS patients undergoing PCI. 2013. Accessed 27 Aug 2024."},{"key":"2287_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003877","author":"H Wu","year":"2025","unstructured":"Wu H, Xu L, Bao L, et al. Efficacy and safety of bevifibatide in patients with acute coronary syndrome undergoing percutaneous coronary intervention (BES-PCI): a multicenter, randomized, double-blinded, placebo-controlled, phase III trial. Chin Med J (Engl). 2025. https:\/\/doi.org\/10.1097\/CM9.0000000000003877.","journal-title":"Chin Med J (Engl)"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02287-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02287-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02287-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:00:52Z","timestamp":1774069252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02287-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02287-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Simon Fung is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}